Related Experiment Videos
Azithromycin does not cure pityriasis rosea
1Wayne State University School of Medicine, The Carman and Ann Adams Department of Pediatrics, Children's Hospital of Michigan, Detroit, MI 48201, USA.
Pediatrics
|May 3, 2006
Summary
Azithromycin did not cure pityriasis rosea (PR) in children. This study found similar cure and partial resolution rates between azithromycin and placebo treatments for this common skin condition.
Area of Science:
- Dermatology
- Pediatrics
- Pharmacology
Background:
- Pityriasis rosea (PR) is a common, self-limiting skin condition in children with an unknown etiology.
- Previous research suggested erythromycin may be effective, prompting investigation into alternative treatments.
Purpose of the Study:
- To evaluate the efficacy of azithromycin, an antibiotic with a favorable pharmacokinetic profile, in treating pediatric pityriasis rosea.
- To determine if azithromycin offers a therapeutic advantage over placebo for PR.
Main Methods:
- A randomized, double-blind, placebo-controlled trial involving 49 children diagnosed with pityriasis rosea.
- Participants received either azithromycin (12 mg/kg/day for 5 days) or a placebo.
- Outcomes assessed included the appearance of new lesions and the resolution of existing lesions over a 4-week follow-up period.
Main Results:
- The cure rates for pityriasis rosea were comparable between the group treated with azithromycin and the placebo group.
- Partial resolution rates were also similar across both treatment arms.
- No significant difference in treatment efficacy was observed.
Conclusions:
- Azithromycin is not an effective treatment for pityriasis rosea in children.
- The study did not support the use of azithromycin for managing this pediatric skin condition.